New drug cocktail shows promise for tough lung cancer

NCT ID NCT03575793

First seen Jan 21, 2026 · Last updated Apr 25, 2026 · Updated 10 times

Summary

This study tested a combination of three drugs (nivolumab, ipilimumab, and plinabulin) in 39 adults with recurrent small cell lung cancer that had worsened after initial chemotherapy. The goal was to find the safest dose of plinabulin and see if the combo could shrink tumors or delay cancer growth. The approach aims to control the disease rather than cure it, as ongoing management is typically needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope

    Duarte, California, 91010, United States

  • Erlanger Health System

    Chattanooga, Tennessee, 37403, United States

  • Henry Ford Health System

    Detroit, Michigan, 48202, United States

  • Indiana University Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana, 46202, United States

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey, 08903, United States

  • University of Illinois Cancer Center

    Chicago, Illinois, 60612, United States

  • University of Minnesota

    Minneapolis, Minnesota, 55455, United States

Conditions

Explore the condition pages connected to this study.